Cited by 309Immunotherapy and Immune ResponsesRNA Interference and Gene DeliveryT-cell and B-cell Immunology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

Kreiter, Sebastian, Selmi, Abderraouf, Diken, Mustafa, Koslowski, Michael, Britten, Cedrik M., Huber, Christoph, Türeci, Özlem, Sahin, Ugur·2010·Cancer Research

DOI 10.1158/0008-5472.can-10-0699

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Although naked antigen-encoding RNA has entered clinical testing, basic knowledge on how to apply this promising novel vaccine format is still pending. By comparing different administration routes, we observed surprisingly potent antigen-specific T-cell immunity upon intranodal injection of naked antigen-encoding RNA. RNA was selectively uptaken by resident dendritic cells, propagated a T-cell attracting and stimulatory intralymphatic milieu, and led to efficient expansion of antigen-specific CD8+ as well as CD4+ T cells. By intranodal treatment of mice with repeated cycles of RNA, we achieved de novo priming of naïve T cells, which became potent cytolytic effectors capable of homing to primary and secondary lymphatic tissues as well as memory T cells. In tumor-bearing mice intralymphatic RNA vaccination elicited protective and therapeutic antitumor immune responses, resulting in a remarkable survival benefit as compared with other treatment regimens. This is the first report of strong systemic antigen-specific Th1-type immunity and cancer cure achieved with naked antigen-encoding RNA in preclinical animal models. Cancer Res; 70(22); 9031–40. ©2010 AACR.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-0699

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Immunobiology of Dendritic Cells
Banchereau, J., Brière, F., Caux, C., Davoust, J. M., Lebecque, S., Liu, Y., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,755
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
Lutz, M. B., Kukutsch, N. A., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,972
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction
Castellino, F., Huang, A. Y.-C., Altan-Bonnet, G. Y., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 847
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Self-citation
Inflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells
Curtsinger, J., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K., & Mescher, M. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3256 · Cited by 610
Cutting Edge: Generation of Splenic CD8+ and CD8− Dendritic Cell Equivalents in Fms-Like Tyrosine Kinase 3 Ligand Bone Marrow Cultures
Naik, S. H., Proietto, A. I., Wilson, N. S., Dakic, A., Schnorrer, P., Fuchsberger, M., Lahoud, M. H., O’Keeffe, M. A., Shao, Q.-X., Chen, W. F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6592 · Cited by 551

Show all 34 references

Sorted by citations

Items 101–200 of 309

Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Şahin, U. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1288 · Cited by 74
Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates
Tan, L., Zheng, T., Li, M., Zhong, X., Tang, Y., Qin, M., & Sun, X. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00725-4 · Cited by 73
Messenger RNA (mRNA) nanoparticle tumour vaccination
Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 71
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
Paret, C., Simon, P., Vormbrock, K., Bender, C., Kölsch, A. C., Breitkreuz, A., Yildiz, Ö., Omokoko, T., Hubich-Rau, S., Hartmann, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4516 · Cited by 65
Self-citation
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes
Sayour, E. J., Méndez‐Gómez, H. R., & Mitchell, D. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102890 · Cited by 67
Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 65
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Personalized cancer neoantigen vaccines come of age
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018) · Theranostics · doi:10.7150/thno.24387 · Cited by 63
Tumor Cell-Based Vaccine: An Effective Strategy for Eradication of Cancer Cells
Sadeghi, S. A., Bolhassani, A., & Aghasadeghi, M. R. (2022) · Immunotherapy · doi:10.2217/imt-2022-0036 · Cited by 61
mRNA
Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22661 · Cited by 59
Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets
Geginat, J., Nizzoli, G., Paroni, M., Maglie, S., Larghi, P., Pascolo, S., & Abrignani, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00527 · Cited by 63
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy
Supabphol, S., Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896702 · Cited by 60
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 63
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes
Kowalska, J., del Nogal, A. W., Darżynkiewicz, Z. M., Buck, J., Nicola, C., Kuhn, A. N., Łukaszewicz, M., Zuberek, J., Strenkowska, M., Ziemniak, M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku757 · Cited by 56
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines
Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., & Heidenreich, R. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6481-9_5 · Cited by 57
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
Perche, F., Clemençon, R., Schulze, K., Ebensen, T., Guzmán, C. A., & Pichon, C. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.014 · Cited by 55
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models
Farzani, T. A., Földes, K., Ergünay, K., Gürdal, H., Baştuğ, A., & Özkul, A. (2019) · Vaccines · doi:10.3390/vaccines7030115 · Cited by 55
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58
Polyamine‐Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery
Li, J., He, Y., Wang, W., Wu, C., Hong, C., & Hammond, P. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707466 · Cited by 55
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Mochida, Y., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.022 · Cited by 56
Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination
Uchida, S., Yoshinaga, N., Yanagihara, K., Yuba, E., Kataoka, K., & Itaka, K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.033 · Cited by 52
Messenger RNA‐based vaccines: progress, challenges, applications
Kramps, T., & Probst, J. (2013) · WIREs RNA · doi:10.1002/wrna.1189 · Cited by 50
Introduction to RNA Vaccines
Kramps, T., & Elbers, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_1 · Cited by 53
Vaccines against influenza A viruses in poultry and swine: Status and future developments
Rahn, J., Hoffmann, D., Harder, T., & Beer, M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.052 · Cited by 51
Immunotherapy for Medulloblastoma: Current Perspectives
Kabir, T., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s198162 · Cited by 51
A liposomal RNA vaccine inducing neoantigen-specific CD4 + T cells augments the antitumor activity of local radiotherapy in mice
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49
Self-citation
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity
Granot, T., Yamanashi, Y., & Meruelo, D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.215 · Cited by 47
Whole Blood Cells Loaded with Messenger RNA as an Anti‐Tumor Vaccine
Phua, K. K. L., Boczkowski, D., Dannull, J., Pruitt, S. K., Leong, K. W., & Nair, S. K. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201300512 · Cited by 46
Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)
Guardo, A. C., Joe, P. T., Miralles, L., Bargalló, M. E., Mothe, B., Krasniqi, A., Heirman, C., García, F., Thielemans, K., Brander, C., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001276 · Cited by 46
mRNA Cancer Vaccines—Messages that Prevail
Grunwitz, C. R., & Kranz, L. M. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_509 · Cited by 47
Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
Sköld, A. E., van Beek, J. J. P., Sittig, S. P., Bakdash, G., Tel, J., Schreibelt, G., & de Vries, I. J. M. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1746-9 · Cited by 45
mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
Diken, M., Kreiter, S., Vascotto, F., Selmi, A., Attig, S., Diekmann, J., Huber, C., Türeci, Ö., & Sahin, U. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0046 · Cited by 45
Self-citation
Current status and perspectives of immune-based therapies for hepatocellular carcinoma
Aerts, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.253 · Cited by 45
Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
Benteyn, D., Anguille, S., Lint, S. V., Heirman, C., Nuffel, A. M. T. V., Corthals, J., Ochsenreither, S., Waelput, W., Beneden, K. V., Breckpot, K., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.54 · Cited by 44
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Impact of nanoparticle properties on immune cell interactions in the lymph node
Farooq, M. A., Johnston, A. P. R., & Trevaskis, N. L. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.039 · Cited by 45
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses
Murthy, V., Minehart, J. C., & Sterman, D. H. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx097 · Cited by 44
mRNA vaccination as a safe approach for specific protection from type I allergy
Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.168 · Cited by 42
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
Boisguérin, V., Castle, J. C., Löewer, M., Diekmann, J., Mueller, F., Britten, C. M., Kreiter, S., Türeci, Ö., & Şahin, U. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.820 · Cited by 42
Self-citation
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Vormehr, M., Schrörs, B., Boegel, S., Löwer, M., Türeci, Ö., & Şahin, U. (2015) · Journal of Immunology Research · doi:10.1155/2015/595363 · Cited by 44
Self-citation
Nucleic acid-based therapy for coronavirus disease 2019
Piyush, R., Rajarshi, K., Chatterjee, A., Khan, R., & Ray, S. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05007 · Cited by 44
Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy
Yang, X., Fan, J., Wu, Y., Ma, Z., Huang, J., Zhang, Y., Zhou, Z. M., Mo, F., Liu, X., Yuan, H., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102443 · Cited by 42
Dendritic Cell Engineering for Tumor Immunotherapy: from Biology to Clinical Translation
Bhargava, A., Mishra, D. K., Banerjee, S., & Mishra, P. K. (2012) · Immunotherapy · doi:10.2217/imt.12.40 · Cited by 42
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
The messenger's great message for vaccination
Pascolo, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1000871 · Cited by 40
Strong Immune Responses Induced by Direct Local Injections of Modified mRNA-Lipid Nanocomplexes
Arya, S., Lin, Q., Zhou, N., Gao, X., & Huang, J.-D. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.12.044 · Cited by 39
Intralymphatic Immunotherapy: From the Rationale to Human Applications
Senti, G., Johansen, P., & Kündig, T. M. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_133 · Cited by 38
Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics
Kuhn, A. N., Diken, M., Kreiter, S., Vallazza, B., Türeci, Ö., & Sahin, U. (2011) · RNA Biology · doi:10.4161/rna.8.1.13767 · Cited by 39
Self-citation
Immunotherapy for Pediatric Brain Tumors
Sayour, E. J., & Mitchell, D. A. (2017) · Brain Sciences · doi:10.3390/brainsci7100137 · Cited by 38
New routes for allergen immunotherapy
Johansen, P., Moos, S. C. V., Mohanan, D., Kündig, T. M., & Senti, G. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21948 · Cited by 37
Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer
Kerr, M. D., McBride, D. A., Chumber, A. K., & Shah, N. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1811673 · Cited by 40
Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines
Phua, K. K. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/680620 · Cited by 35
Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials
Karimi-Sani, I., Molavi, Z., Naderi, S., Mirmajidi, S. H., Zare, I., Naeimzadeh, Y., Mansouri, A., Tajbakhsh, A., Savardashtaki, A., & Sahebkar, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02882-x · Cited by 39
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 35
RNA pulsed dendritic cells: An approach for cancer immunotherapy
Garg, N. K., Dwivedi, P., Prabha, P. S., & Tyagi, R. K. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.027 · Cited by 35
Lentiviral Vectors: A Versatile Tool to Fight Cancer
Emeagi, P. U., Goyvaerts, C., Maenhout, S. K., Pen, J. J., Thielemans, K., & Breckpot, K. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040011 · Cited by 31
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy
Moos, S. C. V., Kündig, T. M., & Senti, G. (2011) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2011.02.012 · Cited by 31
Trial watch: DNA-based vaccines for oncological indications
Pierini, S., Perales-Linares, R. F., Uribe‐Herranz, M., Pol, J. G., Zitvogel, L., Kroemer, G., Facciabene, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398878 · Cited by 29
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu, L., Ma, W., Johnson, C. H., Khan, S. A., Irwin, M. L., & Pusztai, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.048 · Cited by 30
mRNA vaccination in breast cancer: current progress and future direction
Jiang, X., & Liu, Q. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04805-z · Cited by 29
Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
Joe, P. T., Christopoulou, I., Hoecke, L. V., Schepens, B., Ysenbaert, T., Heirman, C., Thielemans, K., Saelens, X., & Aerts, J. L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1991-3 · Cited by 29
Precision T-cell therapy targets tumours
Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28
The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines
Chakraborty, C., Majumder, A., Bhattacharya, M., Chatterjee, S., & Lee, S. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100177 · Cited by 29
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 33
mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 31
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers
Anderson, K. S., Erick, T. K., Chen, M., Daley, H., Campbell, M., Colson, Y. L., Mihm, M. C., Zakka, L. R., Hopper, M., Barry, W. T., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06562-y · Cited by 25
Current Status of Messenger RNA Delivery Systems
Stanton, M. G. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0726 · Cited by 26
Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs
Loomis, K. H., Kirschman, J. L., Bhosle, S. M., Bellamkonda, R. V., & Santangelo, P. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01753j · Cited by 24
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Abdellatif, A. A. H., Younis, M. A., Alsowinea, A. F., Abdallah, E. M., Abdel‐Bakky, M. S., Al-Subaiyel, A., Hassan, Y. A., & Tawfeek, H. M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113111 · Cited by 24
Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis
López‐Santalla, M., Mancheño‐Corvo, P., Escolano, A., Menta, R., DelaRosa, O., Abad, J. L., Büscher, D., Redondo, J. M., Bueren, J. A., Dalemans, W., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00638 · Cited by 24
Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis
Mancheño‐Corvo, P., López‐Santalla, M., Menta, R., DelaRosa, O., Mulero, F., del Río, B., Ramirez, C., Büscher, D., Bueren, J. A., López-Belmonte, J. L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00462 · Cited by 23
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response
Vascotto, F., Petschenka, J., Walzer, K. C., Vormehr, M., Brkic, M., Strobl, S., Rösemann, R., Diken, M., Kreiter, S., Türeci, Ö., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601480 · Cited by 23
Self-citation
Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs
Fumoto, S., Yamamoto, T., Okami, K., Maemura, Y., Terada, C., Yamayoshi, A., & Nishida, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020159 · Cited by 23
mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity
Cafri, G., Sharbi‐Yunger, A., Tzehoval, E., Alteber, Z., Gross, T., Vadai, E., Margalit, A., Gross, G., & Eisenbach, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.90 · Cited by 20
Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
Gómez, C. E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., Sorzano, C. Ó. S., Sánchez-Corzo, C., Plana, M., García, F., et al. (2021) · Vaccines · doi:10.3390/vaccines9090959 · Cited by 21
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies
Diken, M., Kreiter, S., Selmi, A., Türeci, Ö., & Şahin, U. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_15 · Cited by 19
Self-citation
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21
Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens
Kamigaki, T., Takimoto, R., Okada, S., Ibe, H., Oguma, E., & Goto, S. (2024) · Anticancer Research · doi:10.21873/anticanres.17196 · Cited by 20
Pathways for macrophage uptake of cell-free circular RNAs
Amaya, L., Abe, B. T., Liu, J., Zhao, F., Zhang, W. L., Chen, R., Li, R., Wang, S., Kamber, R. A., Tsai, M.-C., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.022 · Cited by 18
Intralymphatic Immunotherapy and Vaccination in Mice
Johansen, P., & Kündig, T. M. (2014) · Journal of Visualized Experiments · doi:10.3791/51031 · Cited by 18
Exploiting dendritic cells in the development of cancer vaccines
Bracci, L., Capone, I., Moschella, F., Proietti, E., & Belardelli, F. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836905 · Cited by 18
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
Rechberger, J. S., Toll, S. A., Vanbilloen, W. J. F., Daniels, D. J., & Khatua, S. (2023) · Diagnostics · doi:10.3390/diagnostics13142398 · Cited by 19
mRNA: Delivering an Antitumor Message?
Lint, S. V., Thielemans, K., & Breckpot, K. (2011) · Immunotherapy · doi:10.2217/imt.11.28 · Cited by 17
Lipoplexes Carrying mRNA Encoding Gag Protein Modulate Dendritic Cells to Stimulate HIV-Specific Immune Responses
Haes, W. D., Rejman, J., Pollard, C., Merlin, C., Vekemans, M., Florence, É., Smedt, S. C. D., Grooten, J., Vanham, G. L., Koker, S. D., et al. (2012) · Nanomedicine · doi:10.2217/nnm.12.97 · Cited by 17

Authors: Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U.
Affiliations: Johannes Gutenberg University Mainz (DE)
Authors' Affiliations: 1Center for Translational Oncology and Immunology (TRON), 2Ribological, Biontech AG, and 3Department of Internal Medicine III, Division of Translational and Experimental Oncology, Johannes Gutenberg University, Mainz, Germany
ORCID: Kreiter, Sebastian
Diken, Mustafa
Koslowski, Michael
Britten, Cedrik M.
Türeci, Özlem
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-11-14
Volume: 70
Issue: 22
Pages: 9031-9040
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-10-0699
OpenAlex: W2125677437
Cited by: 309
References: 34
Citations by year: 2026: 10 · 2025: 16 · 2024: 25 · 2023: 30 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 13 · 2018: 17 · 2017: 20 · 2016: 19 · 2015: 23 · 2014: 21 · 2013: 22 · 2012: 13
FWCI: 6.59
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Bundesministerium für Bildung und Forschung
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: intranodal injection, dendritic cells, CD8+ T cells, CD4+ T cells, Th1 response, antitumor immunity, prophylactic and therapeutic vaccination, T cell homing, memory T cells, cancer immunotherapy
MeSH terms: Animals, Antigens, Cytotoxicity, Immunologic, Dendritic Cells, Flow Cytometry, Immunization, Lymph Nodes, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, RNA, CD4-Positive T-Lymphocytes, Survival Analysis, Mice, Knockout, CD8-Positive T-Lymphocytes, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks